Sign inJoin waitlistJoin the waitlist

Marina Konopleva

Associate Director, Translational Science, Montefiore Einstein Comprehensive Cancer Center · Montefiore Medical Center/Albert Einstein College of Medicine

Credentials: · · · · ·

History

Translational Blood Cancer Institute Center · Montefiore Medical Center/Albert Einstein College of Medicine
Present
Montefiore Medical Center/Albert Einstein College of Medicine
Present
Montefiore Medical Center/Albert Einstein College of Medicine
Present

Ivan P. Pavlov Higher Institute of Medicine
1993–1994
Ivan P. Pavlov Higher Institute of Medicine
1990–1993
Saint Petersburg Pavlov State Medical University
1986–1990

Research

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
New England Journal of Medicine · 2020 · 2,437 citations
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Blood · 2019 · 1,529 citations
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia
New England Journal of Medicine · 2014 · 1,124 citations

Hagop Kantarjian
311 papers
Michael Andreeff
260 papers
Elias Jabbour
236 papers
Naval Daver
227 papers
Tapan Kadia
223 papers
Courtney DiNardo
206 papers
Guillermo Garcia-Manero
196 papers
GB
Gautam Borthakur
190 papers
Naveen Pemmaraju
164 papers
Jorge Cortes
148 papers
Nicholas Short
136 papers · 18 as a fellow
Nitin Jain
117 papers

Grants

Targeting Inflammatory RAS-Mutated AML Leukemia Stem Cells
National Cancer Institute · R01
PI · $573.1K · Icahn School of Medicine at Mount Sinai
2026–2031
Therapeutic Targeting of Mitochondrial OxPhos and Lipid Remodeling in Relapsed AML
National Cancer Institute · R21
PI · $429.5K · University of Texas at Austin
2026–2028
Interrogating Erythroid Differentiation and BCL-XL Axis in TP53-Mutated Acute Myeloid Leukemia
National Cancer Institute · R21
Contact PI · $442.8K · Albert Einstein College of Medicine
2026–2028
Dual Targeting of AML by BCL-2 Inhibition and by CD123-Directed NK Engager/NK Cell Immune Therapies
National Cancer Institute · R21
Contact PI · $432K · Albert Einstein College of Medicine
2026–2028

Clinical trials

Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Principal investigator · Terminated · Phase 1
M.D. Anderson Cancer Center
2016–2022
LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Principal investigator · Completed · Phase 1
M.D. Anderson Cancer Center
2016–2019
Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias
Principal investigator · Completed · Phase 1
M.D. Anderson Cancer Center
2012–2016
AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2010–2014